Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Prevention of HIV/AIDS (X3)


Organizer(s) Brigitte Autran and Scott M. Hammer
March 22—27, 2009
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 24, 2008
Late Abstract Deadline: Dec 22, 2008
Scholarship Deadline: Nov 24, 2008
Early Registration Deadline: Jan 22, 2009

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation


Summary of Meeting:
Most recent research efforts on the prevention of HIV and AIDS has focused on T cell-based vaccines but it is admitted this approach will not prevent HIV and needs to be strengthened by novel approaches to generate HIV neutralizing antibodies. The recent successes or failures of alternative methods of HIV prevention (e.g., microbicides, circumcision), or of AIDS prevention (therapeutic vaccines) should help better understand how HIV vaccines can be used, and require sharing basic understanding and results with the prophylactic vaccine field. However the recent negative results of a major HIV vaccine trial have substantially disorganized the field. The goals of the meeting are therefore to focus on the most recent key advances in the understanding of (1) how HIV can be controlled at entry and after infection in 3 joint sessions with the concurrent “HIV Immunobiology” meeting, (2) how T cell-based or antibody-based HIV vaccines can be improved, and (3) what are the results of the current vaccine trials and those of alternative methods of HIV or AIDS prevention and how can they help at re-orientating vaccine researches. Two workshops will provide key information on the definition of immune correlates of protection and their analysis in clinical trials.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 22

15:00—19:30
Registration

Longs Peak Foyer
18:30—19:30
Refreshments

Longs Peak Foyer
19:30—21:30
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Longs Peak / Grays Peak
* Brigitte Autran, Hôpital Pitié-Salpétrière, UPMC, France

* Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland

Françoise Barré-Sinoussi, Institut Pasteur, France
HIV Diversity and Pathogenesis

Rafi Ahmed, Emory University School of Medicine, USA
Vaccination and Immune Memory


MONDAY, MARCH 23

07:00—08:00
Breakfast

Red Cloud / Shavano / Torreys
08:00—11:00
Host Genomics and HIV Disease (Joint)
Meeting has ended...abstracts no longer viewable online.

Columbine Ballroom
* Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland

Amalio Telenti, Centre Hospitalier Universitaire Vaudois, Switzerland
Evolutionary and Integrative Genomics of Susceptibility to HIV

Mary Carrington, Frederick National Laboratory for Cancer Research, USA
Immunogenetic Variation Characterizing Exceptional Control of HIV

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
HIV Controllers: A Model for T Cell Vaccination?

Ioannis Theodorou, INSERM U543, France
Short Talk: Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study

David I. Watkins, University of Miami, Miller School of Medicine, USA
Vaccine-Induced Cellular Responses Control Acute SIV Replication after Heterologous Challenge

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Red Cloud / Shavano / Torreys
11:00—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Castle Peaks
13:00—22:00
Poster Viewing

Red Cloud / Shavano / Torreys
16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:15
The Bigger Picture: Microbicides, Circumcision and Drugs for Prevention
Meeting has ended...abstracts no longer viewable online.

Quandary
* Glenda Gray, South African Medical Research Council, South Africa

Bertran Auvert, CHU Ambroise Paré, France
Circumcision: Uptake and Impact

Minh H. Dinh, Northwestern University Feinberg School of Medicine, USA
Short Talk: HIV-1 Interactions with Adult Human Penile Epithelium

Barbara L. Shacklett, University of California, Davis, USA
Short Talk: Do Mucosal T Cell Responses to HIV-1 Matter?

Carolina Herrera, Imperial College, UK
Short Talk: Early Colorectal Responses to HIV-1 and Modulation by Microbicides

Gilda Tachedjian, Burnet Institute, Australia
Short Talk: Enhancement of HIV-1 Infection is Not Intrinsic to Polyanion-Based Microbicides

Myron S. Cohen, University of North Carolina at Chapel Hill, USA
Antiretroviral Therapy to Prevent Sexual Transmission of HIV-1

17:00—19:00
Hiding from Immunity: Reservoirs and Latency
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peaks
* Douglas D. Richman, University of California, San Diego, USA

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Quantitative Analysis of the Control of HIV Replication by Drugs and Vaccines

Joel N. Blankson, Johns Hopkins School of Medicine, USA
HIV-1 Latency and Low Level Viremia in Elite Suppressors

Dana H. Gabuzda, Dana Farber Cancer Institute, USA
Macrophage Reservoirs

Matthias Geyer, Max Planck Institute for Molecular Physiology, Germany
Short Talk: Structural Insights into the Cyclin T1–Tat–TAR RNA Transcription Activation Complex

19:15—20:00
Social Hour with Lite Bites

Red Cloud / Shavano / Torreys
19:30—22:00
Poster Session 1

Red Cloud / Shavano / Torreys

TUESDAY, MARCH 24

07:00—08:00
Breakfast

Red Cloud / Shavano / Torreys
08:00—11:00
Immune Control of HIV and Virus Escape (Joint)
Meeting has ended...abstracts no longer viewable online.

Columbine Ballroom
* Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland
Immune Correlates of Protection to HIV

Joseph Michael McCune, University of California, San Francisco, USA
Short Talk: Immune Control in Pathogenic and Nonpathogenic SIV Infection

Mark Connors, NIAID, National Institutes of Health, USA
Short Talk: Effective Control of HIV by CD8+ T-Cells is Associated with Infected CD4+ T Cell Elimination: Ramifications for T Cell Based Vaccines

Carl W. Dieffenbach, NIAID, National Institutes of Health, USA
Short Talk: Stimulus Package: NIH and the ARRA

Philip J. Goulder, University of Oxford, UK
HIV Escape and T-Cell Control of HIV

George M. Shaw, University of Pennsylvania, USA
HIV-1 Sequences in Acute and Early Infection Reveal the Genetic Identity, Biological Phenotype, and Precise Evolutionary Pathways of Transmitted/Founder Viruses and their Progeny

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Red Cloud / Shavano / Torreys
11:00—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Castle Peaks
13:00—22:00
Poster Viewing

Red Cloud / Shavano / Torreys
14:30—15:30
Workshop 1A: New Therapeutics

Grays/Longs Peaks
* Dana H. Gabuzda, Dana Farber Cancer Institute, USA

Daria J. Hazuda, Merck Research Laboratories, USA
Integrase Inhibitors

Mike Westby, Pfizer Global Research and Development, UK
CCR5 Antagonists as HIV Entry Inhibitors

Navid Madani, Dana Farber Cancer Institute, USA
New Entry Inhibitors: Interaction of Small-Molecule CD4 Mimics with a Highly Conserved Pocket on the HIV gp120 Envelope Glycoprotein

15:30—16:30
Workshop 1B: Th17 Cells

Grays/Longs Peaks
* Robert F. Siliciano, Johns Hopkins University School of Medicine, USA

Aimee El Hed, New York University School of Medicine, USA
Human Th17 Cells are Highly Susceptible to CCR5-Tropic HIV Infection and are Preferentially Depleted in Infected Individuals

Nicolas Manel, Institut Curie, France
The Differentiation of Human Th17 Cells Requires TGF-beta and Induction of the Nuclear Receptor RORgammat and this Renders T Cells more Susceptible to HIV-1 Infection

Petronela Ancuta, Centre de Recherche de l'Universite de Montreal, Canada
HIV Replicates in CCR6+IFN-gamma+IL-17+ but Not CCR6negIFN-gamma+IL-10+ Primary CD4+ T-Cell Subsets

Anna Aldovini, Boston Children's Hospital and Harvard Medical School, USA
Tat-Induced FOXO3a is a Key Mediator of Apoptosis in HIV-1-Infected Human CD4+ T-Lymphocytes

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:15
How to Improve Vaccine Efficacy? Adjuvants, Route of Administration...
Meeting has ended...abstracts no longer viewable online.

Quandary
* David I. Watkins, University of Miami, Miller School of Medicine, USA

Bali Pulendran, Emory University, USA
Modulating Vaccine Responses with Innate Immunity

Susan W. Barnett, Bill & Melinda Gates Foundation, USA
HIV Antigen Discovery and Novel Vaccine Deliveries Using Recombinant Alphavirus Replicon Particles and Adjuvanted Proteins

Christopher J. Miller, University of California, Davis, USA
A T Cell Vaccine that Elicits Mucosal CD8+ Effector Cells in a Setting of Minimal Immune Activation Can Protect Rhesus Monkeys from Vaginal SIV Challenge

Barbara K. Felber, NCI, National Institutes of Health, USA
Short Talk: Electroporation of Optimized DNA Vaccines Leads to Greatly Enhanced Systemic and Mucosal Immune Responses and Control of Pathogenic SIVmac251 Challenge: Antibodies Contribute to Virus Containment

Johannes Fabian Scheid, Rockefeller University, USA
Short Talk: Search for Broadly Neutralizing Antibodies against HIV using a Single Cell Approach

17:00—19:00
Models of HIV Immunobiology
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peaks
* Frank Kirchhoff, University of Ulm, Germany

Guido Silvestri, Emory University School of Medicine, USA
SIV Infection of African Monkeys: A New Paradigm for AIDS Pathogenesis and Vaccines

Cecilia Cheng-Mayer, Aaron Diamond AIDS Research Center, USA
Coreceptor switching in the SHIV/macaque model

Sarah L. Rowland-Jones, Oxford University, UK
Long-term non-progression with HIV infection: lessons from HIV-2

19:00—20:00
Social Hour with Lite Bites

Red Cloud / Shavano / Torreys
19:30—22:00
Poster Session 2

Red Cloud / Shavano / Torreys

WEDNESDAY, MARCH 25

07:00—08:00
Breakfast

Red Cloud / Shavano / Torreys
08:00—11:00
How to Generate Vaccine Efficacy against HIV? T Cell-Based and B-Cell Based Vaccines
Meeting has ended...abstracts no longer viewable online.

Quandary
* Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland

Barton F. Haynes, Duke University Medical Center, USA
What Does a Successful HIV-1 Vaccine Need To Do? Clues From Acute HIV-1 Infection

Dan H. Barouch, Harvard Medical School/Beth Israel Deaconess Medical Center, USA
Novel Adenovirus Vector-Based Vaccines for HIV-1

Dennis R. Burton, The Scripps Research Institute, USA
Mechanisms of Antibody Protection Against HIV

Peter D. Kwong, NIAID, National Institutes of Health, USA
Structure-Based Envelope Immunogens

Amitinder Kaur, New England Regional Primate Research Center, USA
Short Talk: Protective Efficacy of a Replication-Defective Herpes Simplex Virus-based AIDS Vaccine Against High Dose Intra-Rectal SIVmac239 Challenge

08:00—11:00
New Insights in HIV Replication
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peaks
* Michael H. Malim, King's College London, UK

Frank Kirchhoff, University of Ulm, Germany
Role of Nef in vivo and in vitro

Christopher Aiken, Vanderbilt University School of Medicine, USA
Cyclophilin A and HIV-1 Uncoating

Nathaniel R. Landau, New York University School of Medicine, USA
Vpr and DNA Damage

John C. Guatelli, University of California, San Diego, USA
Short Talk: Vpu Antagonizes BST-2-Mediated Restriction of HIV-1 Release via b-TrCP and Endo-Lysosomal Trafficking

Andres Finzi, CRCHUM, Université de Montréal, Canada
Short Talk: A Layered Structure in the HIV-1 gp120 Inner Domain Regulates gp41 Interaction and Facilitates Transitions into the CD4-Bound Conformation

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Red Cloud / Shavano / Torreys
13:00—22:00
Poster Viewing

Red Cloud / Shavano / Torreys
14:30—16:30
Workshop 1: Which Immune Correlates of Protection against HIV? How to Measure T Cell and B Cell Correlates? Supported in part by the French Agency for AIDS Research (ANRS)

Quandary
* Richard A. Koup, NIAID, National Institutes of Health, USA

Asier Sáez-Cirión, Institut Pasteur, France
The Strong HIV Suppressive Capacity of CD8+ T Cells from HIV Controllers is Associated with Gag-Specific CD8+ T Cell Responses

Adam R. Hersperger, Thomas Jefferson University, USA
HIV-Specific CD8 T Cells from Elite Controllers Rapidly Upregulate Perforin

Meritxell Genescà, Health Sciences Research Institute Germans Trias i Pujol Foundation, Spain
For the CD8+ T Cells to be Effective in the Context of a Live-Attenuated Vaccine Differential Immune Activation is Critical

Jorge Ramos de Almeida, NIAID, National Institutes of Health, USA
Antigen Sensitivity is a Major Determinant of CD8+ T Cell Efficacy in HIV-1 Infection

Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, USA
Broad Neutralizing Antibody Responses during HIV-1 Infection: Prevalence and Epitope Specificities

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Breadth of Neutralizing Antibodies in HIV+ Serum: Clustering Analysis and Association with Clinical Variables

Ann J. Hessell, Oregon Health & Science University, USA
Complete Protection Provided by Antibodies 2F5 and 4E10 Against Mucosal SHIV BaL Challenge

Vincent Holl, Institute of Virology, France
Identification of HIV-Specific IgG that Inhibit Infection of Mucosal HIV Target Cells

13:30—16:30
NIAID Workshop on Identification and Validation of New Cellular Co-Factors in HIV Replication. Organized by Roger Miller and Opendra Sharma, DAIDS, NIAID. Moderators: Roger Ptak and Warner Greene.
The objective of the workshop will be to discuss the current status of the field; determine the best approach for validating the mechanism of action of host molecules in primary cells; and, promote development of assays which recreate the activity of a cellular co-factor, or a cellular restriction, with the goal of producing a high throughput screening assay for testing chemical compound libraries.

Grays/Longs Peaks
Carl W. Dieffenbach, NIAID, National Institutes of Health, USA
Workshop Objectives

* Roger Ptak, Southern Research Institute, USA
Cataloging the HIV-Human Protein Interaction Network

John A. T. Young, F.Hoffmann-La Roche Ltd, Switzerland
Genome-Wide Screeing of HIV-Host Interactions

Vineet N. KewalRamani, NCI, National Institutes of Health, USA
Regulation of HIV-1 Nuclear Entry

* Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening

Dana H. Gabuzda, Dana Farber Cancer Institute, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening

Tariq M. Rana, University of California, San Diego, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Wrap-Up and Future Directions

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
HIV at the Mucosa: Portal of Entry and Front-Line Defense (Joint)
Meeting has ended...abstracts no longer viewable online.

Columbine Ballroom
* Daniel C. Douek, NIAID, National Institutes of Health, USA

Ashley T. Haase, University of Minnesota, USA
Keynote Address: Quest for Design Principles for an Effective HIV Vaccine/Microbicide in Studies of SIV Pathogenesis

Alison Simmons, Weatherall Institute of Molecular Medicine, UK
Dendritic Cell Factors Required for HIV-1 Infection

Ronald S. Veazey, Tulane National Primate Research Center, USA
_7 Integrin Expression on CD4+ T Cells as a Surrogate Marker for Tracking Intestinal CD4+ T Cell Loss in SIV Infection

Satya Dandekar, University of California, Davis, USA
Short Talk: Mechanisms of Impaired Gut Mucosal Defenses during HIV and SIV Infections

19:00—20:00
Social Hour with Lite Bites

Red Cloud / Shavano / Torreys
19:30—22:00
Poster Session 3

Red Cloud / Shavano / Torreys

THURSDAY, MARCH 26

07:00—08:00
Breakfast

Red Cloud / Shavano / Torreys
07:00—08:00
Poster Setup

Red Cloud / Shavano / Torreys
08:00—11:15
HIV-HSV-2 Interactions and Lessons from Clinical Trials of Preventative Vaccines
Meeting has ended...abstracts no longer viewable online.

Quandary
Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Mechanism behind the HSV-2-HIV Interaction: Subclinical Persistence of HIV Receptor Positive Cells

* Scott M. Hammer, Columbia University, USA
Challenges in Preventative Vaccine Development

Susan P. Buchbinder, San Francisco Department of Public Health, USA
Clinical Endpoints in the Step Study

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Lessons from the HIV-Ad5 Vaccine Phase II Clinical Trial

Merlin L. Robb, Walter Reed Army Institute of Research, USA
Lessons from the Thai ALVAC-gp120 HIV Vaccine Efficacy Trial: A Community Based Study

08:00—11:00
Innate Antiviral Immunity
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peaks
* Christopher Aiken, Vanderbilt University School of Medicine, USA

Michael H. Malim, King's College London, UK
APOBEC3 Proteins and Intrinsic Resistance to HIV-1 Infection

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
The Role of APOBEC3 Enzymes in Counteracting “Retro-Threats”, Both Foreign and Domestic

Greg J. Towers, University College London, UK
Inhibition of Retroviral Infection by TRIMCyp and Tetherin Reveals a Delicate Balance between Viral Countermeasures and Host Restriction

Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland
Epigenetic Control of Retroelements

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00—12:00
Lunch

Red Cloud / Shavano / Torreys
12:00—14:30
Poster Session 4

Red Cloud / Shavano / Torreys
14:30—16:30
Workshop 2: Clinical Trials Design. Supported in part by the French Agency for AIDS Research (ANRS)

Quandary
* Scott M. Hammer, Columbia University, USA

Dean Follmann, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Crossover Designs for HIV Prevention Trials

Peter Gilbert, Fred Hutchinson Cancer Research Center, USA
Leveraging Baseline Characteristics to Improve Prevention Trials

Frances Priddy, International AIDS Vaccine Initiative, USA
HIV Vaccines and PrEP

Heather B. Jaspan, University of Cape Town, South Africa
HIV Vaccine Trials in Adolescents

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Prevention of AIDS: What can we Learn from Therapeutic Vaccines
Meeting has ended...abstracts no longer viewable online.

Quandary
Brigitte Autran, Hôpital Pitié-Salpétrière, UPMC, France
Lessons for Therapeutic Vaccines against HIV for Immune Correlates of Protection against HIV

* Rafick-Pierre Sékaly, Case Western Reserve University, USA
Improving and Modeling of Therapeutic Autologous Dendritic Cell Vaccine for HIV-1 Infection

Stephen J. Kent, University of Melbourne, Australia
Short Talk: Reduced Viremia and Delayed Disease Progression Following Immunotherapy of SIV with Antigen Pulsed Blood

Glenda Gray, South African Medical Research Council, South Africa
HIV Vaccine Trials in South Africa: Looking Forward from Phambili

17:00—19:15
Virus Spread
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peaks
* Alison Simmons, Weatherall Institute of Molecular Medicine, UK

Olivier Schwartz, Institut Pasteur, France
Mechanisms of Direct HIV Lymphocyte-to-Lymphocyte Transfer: Role of “Polysynapses”

Thomas J. Hope, Northwestern University, Feinberg School of Medicine, USA
Interaction of HIV with Cells within Intact Mucosal Tissue

Vincent Piguet, Cardiff University, UK
Mechanisms of DC-T Cell HIV-1 Transmission via an Infectious Synapse

Walther Mothes, Yale University School of Medicine, USA
Short Talk: Retroviral Assembly is Directed Towards Sites of Cell-Cell Contact

Sriram Subramaniam, National Institutes of Health, USA
Short Talk: 3D Architecture of the Virological Synapse and Structural Mechanisms of HIV Entry

19:00—20:00
Social Hour with Lite Bites

Red Cloud / Shavano / Torreys
20:00—23:00
Entertainment

Red Cloud / Shavano / Torreys

FRIDAY, MARCH 27

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI081599-01




We gratefully acknowledge additional support for this conference from:

ANRS, French National Agency for Research on AIDS and Viral Hepatitis Bill & Melinda Gates Foundation
Gilead Sciences, Inc. International AIDS Vaccine Initiative (IAVI)
Office of AIDS Research, NIH Tibotec, Inc.

GenVec, Inc.
 

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676